Scott Weir, PharmD, PhD

Director, Office of Therapeutics, Discovery and Development
Associate Director, Translational Research
Frank B. Tyler Cancer Research Professor in Therapeutic Discovery
sweir@kumc.edu

Scott Weir, PharmD, PhD brings over 22 years of pharmaceutical industry experience to lead the Office of Therapeutics, Discovery and Development.  His leadership, experience and relationships in industry are paving the way for the University of Kansas Cancer Center to attain its goal of being the number one academic generator and developer of oncology drugs. 

Dr. Weir joined the University of Kansas Cancer Center in February 2006 to establish and manage a fully integrated drug discovery and development program through the collaboration of researchers, industry partners, regulatory and technology transfer resources. 

Background

Dr. Weir received his PharmD degree in 1980 from the University of Nebraska College of Pharmacy followed by a PhD in Pharmacokinetics and Biopharmaceutics from the University of Nebraska Medical Center in 1986. 

Dr. Weir joined Marion Laboratories, Inc. in 1986 as a clinical pharmacokineticist.  From 1988 through 1998, Weir assumed a series of management positions with increasing responsibility at Marion Laboratories, Inc., Marion Merrell Dow, Inc. Hoechst Marion Roussel, Inc., and Aventis Pharmaceuticals, Inc.  Dr. Weir was actively involved with R&D reengineering efforts for each of these companies in 1992 and 1997.  He was directly involved in the successful registration of Cardizem CD, Cardizem Injectible, Anzemet Tablets, Anzemet Injectable, Pentasa, Carafate, Rifater, and Allegra.  

Dr. Weir led the global integration and harmonization activities for drug metabolism and pharmacokinetics during the early stages of the Hoechst Marion Roussel Inc. merger.

Dr. Weir currently serves on the Clinical Research Advisory Council for the Kansas City Area Life Sciences Institute.  He is also an Advisory Board Member for Orbis Pharmaceuticals Inc.  Additionally, he is an Advisory Board Member of the “Initiative for Targeted Delivery of Novel Cancer Therapeutics”, a targeted excellence center at Kansas State University.  

University of Kansas Cancer Center

Dr. Weir joined the team in 2006 and holds a professorship in the department of Pharmacology, Toxicology and Therapeutics.  He also holds a courtesy faculty appointment with Pharmaceutical Chemistry in the third national ranked School of Pharmacy at the University of Kansas.  Dr. Weir is the Frank B. Tyler Cancer Research Professor in Therapeutic Discovery. 

Membership Organizations

• Member, American Association of Pharmaceutical Scientists

Recent Publications

1. Robbins DK, Hutcheson SJ, Miller TD, Green VI, Bhargava VO, and Weir SJ:  Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers.  Biopharm Drug Dispos 1997;18(4):325-334.
2. Stoltz M, Arumugham T, Lippert C, Yu D, Bhargava V, Eller, M and Weir SJ:  Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A).  Biopharm Drug Dispos 1997;18(7):645-648.
3. Yu DK, Bhargava VO, and Weir SJ:  Selection of doses for Phase II clinical trials based on pharmacokinetic variability considerations.  J Clin Pharmacol 1997;37(8):673-678.
4. Weir SJ, Dimmitt DC, Lanman RC, Morrill BS, and Giesing, DH:  Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination.  Biopharm Drug Dispos 1998;19(6):365-371.
5. Robbins DK, Castles MA, Pack DJ, Bhargava VJ, and Weir SJ:  Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers.  Biopharm Drug Dispos 1998;19(7):455-463.
6. Russell T, Stoltz M, and Weir SJ:  Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.  Clin Pharmacol Ther 1998;64:612-621.
7. Dimmitt DC, Shah AK, Arumugham T, Cramer MB, Halstenson C, Horton M, and Weir SJ:  Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.  J Clin Pharmacol 1998;38(9):798-806.
8. Dimmitt, DC, Choo YS, Martin, LA, Arumugham T, Hahne WF, and Weir SJ:  Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers:  Part 1.  Biopharm Drug Dispos 1999;20(1):29-39.
9. Dimmitt, DC, Choo YS, Martin, LA, Arumugham T, Hahne WF, and Weir SJ:  Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers:  Part 2.  Biopharm Drug Dispos 1999;20(1):41-48.
10. Jin W, Trzupek JD, Rayl TJ, Broward MA, Vielhauer GA, Weir SJ, Hwang I, and Boger DJ:  A unique class of duocarmycin and CC-1065 analogues subject to reductive activation.  J Am Chem Soc, accepted for publication.